Abeona Therapeutics Stock Gains Momentum Following ZEVASKYN™ Launch

Shares of Abeona Therapeutics advanced 1.46% to $6.95 in the previous session as investor focus sharpened on the company’s upcoming presentations and the ongoing commercial rollout of its newly approved gene therapy, ZEVASKYN.

The company is set to participate in two key investor conferences. A Fireside Chat at the Cantor Global Healthcare Conference is scheduled for today at 4:20 PM Central European Summer Time (MESZ). This will be followed by a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9. These events are viewed as crucial opportunities for management to detail the early commercial progress of its flagship therapy.

The Read more...